Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Christophe Blanquart

Showing results (71-80 of 80) with videos related to

Pageof 8
Sort By:
You have reached the last page of results.This site can display upto 80 results.
Molecular Cancer|October 13, 2018
Brain-derived neurotrophic factor, a new soluble biomarker for malignant pleural mesothelioma involved in angiogenesisPatrick Smeele, Sènan Mickaël d'Almeida, Clément Meiller, et al.
Cancer Letters|December 16, 2019
Cisplatin unleashes Toll-like receptor 3-mediated apoptosis through the downregulation of c-FLIP in malignant mesotheliomaBéatrice Vanbervliet-Defrance, Tiphaine Delaunay, Thomas Daunizeau, et al.
Cancer Research|September 24, 2025
Pharmacogenomic Characterization of a Large Cohort of Patient-Derived Cell Lines Identifies Therapeutic Strategies for Pleural MesotheliomaJean-Baptiste Assié, Clément Meiller, Esther Stern, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|January 17, 2020
Frequent Homozygous Deletions of Type I Interferon Genes in Pleural Mesothelioma Confer Sensitivity to Oncolytic Measles VirusTiphaine Delaunay, Carole Achard, Nicolas Boisgerault, et al.
Stem Cell Research & Therapy|January 11, 2022
Human MuStem cells repress T-cell proliferation and cytotoxicity through both paracrine and contact-dependent pathwaysMarine Charrier, Judith Lorant, Rafael Contreras-Lopez, et al.
Molecular Oncology|December 1, 2022
Preclinical evaluation of CDK4 phosphorylation predicts high sensitivity of pleural mesotheliomas to CDK4/6 inhibitionSabine Paternot, Eric Raspé, Clément Meiller, et al.
Molecular Oncology|October 12, 2022
Heterogeneous RNA editing and influence of ADAR2 on mesothelioma chemoresistance and the tumor microenvironmentAnanya Hariharan, Weihong Qi, Hubert Rehrauer, et al.
ACS Medicinal Chemistry Letters|September 18, 2024
Benign-by-Design SAHA Analogues for Human and Animal Vector-Borne Parasitic DiseasesMichele Rossi, Bianca Martinengo, Eleonora Diamanti, et al.
EMBO Molecular Medicine|December 13, 2021
KRAS signaling in malignant pleural mesotheliomaAntonia Marazioti, Anthi C Krontira, Sabine J Behrend, et al.
The Journal of Clinical Investigation|October 19, 2020
Selective SIRPα blockade reverses tumor T cell exclusion and overcomes cancer immunotherapy resistanceVanessa Gauttier, Sabrina Pengam, Justine Durand, et al.
Pageof 8

Showing results (71-80 of 80) with videos related to

Sort By:
Pageof 8
You have reached the last page of results.This site can display upto 80 results.
Molecular Cancer|October 13, 2018
Brain-derived neurotrophic factor, a new soluble biomarker for malignant pleural mesothelioma involved in angiogenesisPatrick Smeele, Sènan Mickaël d'Almeida, Clément Meiller, et al.
Cancer Letters|December 16, 2019
Cisplatin unleashes Toll-like receptor 3-mediated apoptosis through the downregulation of c-FLIP in malignant mesotheliomaBéatrice Vanbervliet-Defrance, Tiphaine Delaunay, Thomas Daunizeau, et al.
Cancer Research|September 24, 2025
Pharmacogenomic Characterization of a Large Cohort of Patient-Derived Cell Lines Identifies Therapeutic Strategies for Pleural MesotheliomaJean-Baptiste Assié, Clément Meiller, Esther Stern, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|January 17, 2020
Frequent Homozygous Deletions of Type I Interferon Genes in Pleural Mesothelioma Confer Sensitivity to Oncolytic Measles VirusTiphaine Delaunay, Carole Achard, Nicolas Boisgerault, et al.
Stem Cell Research & Therapy|January 11, 2022
Human MuStem cells repress T-cell proliferation and cytotoxicity through both paracrine and contact-dependent pathwaysMarine Charrier, Judith Lorant, Rafael Contreras-Lopez, et al.
Molecular Oncology|December 1, 2022
Preclinical evaluation of CDK4 phosphorylation predicts high sensitivity of pleural mesotheliomas to CDK4/6 inhibitionSabine Paternot, Eric Raspé, Clément Meiller, et al.
Molecular Oncology|October 12, 2022
Heterogeneous RNA editing and influence of ADAR2 on mesothelioma chemoresistance and the tumor microenvironmentAnanya Hariharan, Weihong Qi, Hubert Rehrauer, et al.
ACS Medicinal Chemistry Letters|September 18, 2024
Benign-by-Design SAHA Analogues for Human and Animal Vector-Borne Parasitic DiseasesMichele Rossi, Bianca Martinengo, Eleonora Diamanti, et al.
EMBO Molecular Medicine|December 13, 2021
KRAS signaling in malignant pleural mesotheliomaAntonia Marazioti, Anthi C Krontira, Sabine J Behrend, et al.
The Journal of Clinical Investigation|October 19, 2020
Selective SIRPα blockade reverses tumor T cell exclusion and overcomes cancer immunotherapy resistanceVanessa Gauttier, Sabrina Pengam, Justine Durand, et al.
Pageof 8